5-FU	5-Fluorouracil
ALPPS	Associating liver partition and portal vein ligation for staged hepatectomy
ASCO	American Society of Clinical Oncology
BED	Biologically effective dose
CALI	Chemotherapy-associated liver injury
CAPOX	Capecitabine and oxaliplatin
CI	Confidence interval
CRC	Colorectal cancer
CRLM	Colorectal liver metastases
CT	Computed tomography
DEBIRI	Drug-eluting bead irinotecan
DFS	Disease-free survival
DH	Degree of hypertrophy
dMMR	Deficient mismatch repair
EGFR	Epidermal growth factor receptor
FLR	Future liver remnant
FOLFIRI	Folinic acid, 5-fluorouracil, and irinotecan
FOLFOX	Folinic acid, 5-fluorouracil, and oxaliplatin
FOLFOXIRI	Folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan
FUDR	Floxuridine
Gd-EOB-DTPA	Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
HAI	Hepatic artery infusion
HR	Hazard ratio
HVE	Hepatic vein embolization
LVD	Liver venous deprivation
mCRC	Metastatic colorectal cancer
MDT	Multidisciplinary team
MRI	Magnetic resonance imaging
MSI-H	Microsatellite instability-high
MWA	Microwave ablation
ORR	Objective response rate
OS	Overall survival
PD-1	Programmed cell death protein 1
PFS	Progression-free survival
PHLF	Post-hepatectomy liver failure
POLD1	DNA polymerase delta 1
POLE	DNA polymerase epsilon
PPV	Positive predictive value
PVE	Portal vein embolization
RCT	Randomized controlled trial
RECIST	Response Evaluation Criteria in Solid Tumors
RFA	Radiofrequency ablation
RFS	Recurrence-free survival
SBRT	Stereotactic body radiotherapy
SIRT	Selective internal radiation therapy
TACE	Transarterial chemoembolization
TSH	Two-stage hepatectomy
UNOS	United Network for Organ Sharing
VEGF	Vascular endothelial growth factor
Y-90	Yttrium-90